Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NM-IL-12 + TSEBT
- Development stage
- Unknown
- Lead developer
- Neumedicines
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Topical
01
Overview
NM-IL-12 is a recombinant human interleukin-12 (rHuIL-12) therapy developed as an immunotherapy to enhance antitumor efficacy in cutaneous T-cell lymphoma (CTCL), particularly when combined with low-dose total skin electron beam therapy (TSEBT). Interleukin-12 is a cytokine that stimulates the activity of natural killer (NK) cells and cytotoxic CD8+ T cells, promoting the production of interferon-gamma and shifting immune responses toward a Th1 phenotype. This mechanism aims to improve immune-mediated tumor cell killing while potentially reducing skin-related toxicity associated with radiation. The combination has been evaluated in clinical trials for CTCL, showing promising response rates[1][2][3][4][5].
- Brand names
- HemaMax
- Other names
- rHuIL-12rHuIL12rHuIL 12
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on NM-IL-12 + TSEBT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NM-IL-12 + TSEBT.